Category Pharma/Biotech

Otsuka Reveals Phase 3 Topline Findings for AVP-786 in Treating Agitation Linked to Alzheimer’s Disease Dementia

Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and its parent company, Otsuka Pharmaceutical Co., Ltd. (Otsuka), have disclosed the topline findings from the phase 3 clinical trial of AVP-786 aimed…

Read MoreOtsuka Reveals Phase 3 Topline Findings for AVP-786 in Treating Agitation Linked to Alzheimer’s Disease Dementia